BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 20019066)

  • 1. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis.
    Vastert SJ; van Wijk R; D'Urbano LE; de Vooght KM; de Jager W; Ravelli A; Magni-Manzoni S; Insalaco A; Cortis E; van Solinge WW; Prakken BJ; Wulffraat NM; de Benedetti F; Kuis W
    Rheumatology (Oxford); 2010 Mar; 49(3):441-9. PubMed ID: 20019066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome.
    Grom AA; Villanueva J; Lee S; Goldmuntz EA; Passo MH; Filipovich A
    J Pediatr; 2003 Mar; 142(3):292-6. PubMed ID: 12640378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis.
    Hazen MM; Woodward AL; Hofmann I; Degar BA; Grom A; Filipovich AH; Binstadt BA
    Arthritis Rheum; 2008 Feb; 58(2):567-70. PubMed ID: 18240215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of IRF5 polymorphisms with susceptibility to macrophage activation syndrome in patients with juvenile idiopathic arthritis.
    Yanagimachi M; Naruto T; Miyamae T; Hara T; Kikuchi M; Hara R; Imagawa T; Mori M; Sato H; Goto H; Yokota S
    J Rheumatol; 2011 Apr; 38(4):769-74. PubMed ID: 21239750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent macrophage activation syndrome associated with heterozygous perforin W374X gene mutation in a child with systemic juvenile idiopathic arthritis.
    Unal S; Balta G; Okur H; Aytac S; Cetin M; Gumruk F; Ozen S; Gurgey A
    J Pediatr Hematol Oncol; 2013 Jul; 35(5):e205-8. PubMed ID: 23274377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis.
    Shimizu M; Yokoyama T; Yamada K; Kaneda H; Wada H; Wada T; Toma T; Ohta K; Kasahara Y; Yachie A
    Rheumatology (Oxford); 2010 Sep; 49(9):1645-53. PubMed ID: 20472718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectrum, and clinical and functional implications of UNC13D mutations in familial haemophagocytic lymphohistiocytosis.
    Rudd E; Bryceson YT; Zheng C; Edner J; Wood SM; Ramme K; Gavhed S; Gürgey A; Hellebostad M; Bechensteen AG; Ljunggren HG; Fadeel B; Nordenskjöld M; Henter JI
    J Med Genet; 2008 Mar; 45(3):134-41. PubMed ID: 17993578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome.
    Villanueva J; Lee S; Giannini EH; Graham TB; Passo MH; Filipovich A; Grom AA
    Arthritis Res Ther; 2005; 7(1):R30-7. PubMed ID: 15642140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis.
    de Jager W; Vastert SJ; Beekman JM; Wulffraat NM; Kuis W; Coffer PJ; Prakken BJ
    Arthritis Rheum; 2009 Sep; 60(9):2782-93. PubMed ID: 19714583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble CD25 in serum: a potential marker for subclinical macrophage activation syndrome in patients with active systemic onset juvenile idiopathic arthritis.
    Reddy VV; Myles A; Cheekatla SS; Singh S; Aggarwal A
    Int J Rheum Dis; 2014 Mar; 17(3):261-7. PubMed ID: 24417800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis due to perforin mutations.
    Trizzino A; zur Stadt U; Ueda I; Risma K; Janka G; Ishii E; Beutel K; Sumegi J; Cannella S; Pende D; Mian A; Henter JI; Griffiths G; Santoro A; Filipovich A; Aricò M;
    J Med Genet; 2008 Jan; 45(1):15-21. PubMed ID: 17873118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perforin gene analaysis in an Iranian family with familial hemophagocytic lymphohistiocytosis.
    Galehdari H; Mohammadi E; Andashti B; Naderi A; Molavi MA
    Iran J Immunol; 2007 Jun; 4(2):122-6. PubMed ID: 17652853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Macrophage activation syndrome and systemic onset of juvenile idiopathic arthritis].
    Iglesias Jiménez E; Camacho Lovillo MS; Lirola Cruz MJ; Falcón Neyra D; Neth O
    An Pediatr (Barc); 2010 Mar; 72(3):230-1. PubMed ID: 20097627
    [No Abstract]   [Full Text] [Related]  

  • 14. The incidence of macrophage activation syndrome in children with rheumatic disorders.
    Moradinejad MH; Ziaee V
    Minerva Pediatr; 2011 Dec; 63(6):459-66. PubMed ID: 22075800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable outcome in patients with renal involvement complicating macrophage activation syndrome in systemic onset juvenile rheumatoid arthritis.
    Ramanan AV; Rosenblum ND; Feldman BM; Laxer RM; Schneider R
    J Rheumatol; 2004 Oct; 31(10):2068-70. PubMed ID: 15468377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A91V perforin variation in healthy subjects and FHLH patients.
    Busiello R; Fimiani G; Miano MG; Aricò M; Santoro A; Ursini MV; Pignata C
    Int J Immunogenet; 2006 Apr; 33(2):123-5. PubMed ID: 16611257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic defects in cytolysis in macrophage activation syndrome.
    Zhang M; Behrens EM; Atkinson TP; Shakoory B; Grom AA; Cron RQ
    Curr Rheumatol Rep; 2014; 16(9):439. PubMed ID: 25086802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Davì S; Consolaro A; Guseinova D; Pistorio A; Ruperto N; Martini A; Cron RQ; Ravelli A;
    J Rheumatol; 2011 Apr; 38(4):764-8. PubMed ID: 21285158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition and management of macrophage activation syndrome in juvenile arthritis.
    Kelly A; Ramanan AV
    Curr Opin Rheumatol; 2007 Sep; 19(5):477-81. PubMed ID: 17762614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical spectrum and treatment options of macrophage activation syndrome in the pediatric age.
    Stabile A; Bertoni B; Ansuini V; La Torraca I; Sallì A; Rigante D
    Eur Rev Med Pharmacol Sci; 2006; 10(2):53-9. PubMed ID: 16705949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.